Ultimovacs (ULTI) – Press Releases
-
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
-
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma
-
Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma
-
Ultimovacs ASA: Fourth quarter 2021 result presentation
-
Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study
-
First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer
-
Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
-
Ultimovacs ASA: Third quarter 2021 result presentation
-
Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
-
Ultimovacs ASA - Private placement of new shares successfully placed
-
Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)
-
Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma
-
Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
-
Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
-
Ultimovacs ASA: Second Quarter 2021 Result Presentation
-
Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma
-
Ultimovacs ASA: Invitation to Second Quarter 2021 Results Webcast Presentation
-
Ultimovacs Announces First Patient Enrolled in Phase II FOCUS Trial of UV1 in Head-and-Neck Cancer
-
Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
-
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
-
Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma
-
Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data
-
Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology
-
Ultimovacs ASA: First Quarter 2021 Result Presentation
-
Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings
-
Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting
-
Adam Rogers Joins Next Coast Ventures as Partner
-
Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
-
Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
-
Ultimovacs ASA: Fourth Quarter 2020 Result Presentation
-
Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020
-
Ultimovacs Announces Phase II DOVACC Collaboration Study in Ovarian Cancer With the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncologica
-
Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
-
Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma
-
Next Coast Ventures Expands Entrepreneurs Council with Addition of Adam Rogers
-
Ultimate Software Ranked #2 on PEOPLE’s 50 Companies That Care List
-
Fortune Ranks Ultimate Software #1 on 100 Best Workplaces for Millennials List for Third Consecutive Year
-
Ultimate Software's UltiPro Helps Duluth Trading Grow its Talent and Business
-
Ultimate Software Ranked #1 HR Management Software in TrustRadius 2019 Buyer’s Guide
-
IDG’s Computerworld Ranks Ultimate Software #1 Best Place to Work in IT Among Midsize Companies for Third Consecutive Year
-
Ultimate Software Earns Two Gold Stevie Awards for Customer Service
-
Adam Rogers Promoted to Co-CEO of Ultimate Software, Julie Dodd Promoted to Chief Operating Officer
-
Ultimate Software Completes Agreement to be Acquired by an Investor Group Led by Hellman & Friedman to Operate as a Privately Held Company
-
EastGroup Properties Set to Join S&P MidCap 400; GMS to Join S&P SmallCap 600
-
Ultimate Software Ranks #3 on Best Workplaces in Canada 2019 List
-
Ultimate Software Hosts Annual “Connections” Customer Conference with 4,200 HCM Professionals, Partners, and Analysts
-
Ultimate Software Announces Expiration of “Go-Shop” Period Under Merger Agreement
-
Top-100 Electrical Distributor Uses UltiPro Compensation Management to Address Gaps in Gender Pay During Annual Salary Planning
-
UltiPro Perception Earns Two Excellence in Technology Awards from Brandon Hall Group
-
Ultimate Software's UltiPro Delivers Unprecedented Insight and Drives Business Decisions for $12 Billion Financial Institution
Back to ULTI Stock Lookup
